The Role of Topical Finasteride in Hair Loss Management: Current Evidence and Future Perspectives

REVIEW
Ramadan S. Hussein, Salman Bin Dayel

 
International Journal of Biomedicine. 2023;13(4):236-239.
DOI: 10.21103/Article13(4)_BR
Originally published December 5, 2023

Abstract: 

Hair loss (HL), scientifically known as alopecia, is a prevalent condition affecting individuals globally. Its multifactorial origins encompass genetics, hormonal fluctuations, stress, aging, medical conditions, and medications. The psychological impact of HL on self-esteem, confidence, and overall quality of life has driven the pursuit of effective treatments to rejuvenate hair growth and appearance. Among these treatments, finasteride (FIN) has been employed to address male pattern HL, the most prevalent form of HL in men. This medication hinders the conversion of testosterone to dihydrotestosterone (DHT), a hormone that contributes to hair follicle shrinkage and cessation of hair production. While oral FIN has been widely explored, it entails undesirable side effects and varying effectiveness. This review delves into the role of FIN topical applications as a novel approach for HL treatment.

Keywords: 
hair loss • hair follicle • finasteride • dihydrotestosterone
References: 
  1. Rojhirunsakool S, Suchonwanit P. Parietal scalp is another affected area in female pattern hair loss: an analysis of hair density and hair diameter. Clin Cosmet Investig Dermatol. 2017 Dec 29;11:7-12. doi: 10.2147/CCID.S153768.
  2. Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know? Rev Endocr Metab Disord. 2015 Sep;16(3):177-98. doi: 10.1007/s11154-015-9319-y. 
  3. Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020 Jan;113(1):21-50. doi: 10.1016/j.fertnstert.2019.11.030. 
  4. Ahmed TA, El-Say KM. Transdermal film-loaded finasteride microplates to enhance drug skin permeation: Two-step optimization study. Eur J Pharm Sci. 2016 Jun 10;88:246-56. doi: 10.1016/j.ejps.2016.03.015. 
  5. KLIGMAN AM. The human hair cycle. J Invest Dermatol. 1959 Dec;33:307-16. doi: 10.1038/jid.1959.156. 
  6. Sinclair R. Hair shedding in women: how much is too much? Br J Dermatol. 2015 Sep;173(3):846-8. doi: 10.1111/bjd.13873.
  7. Harrison S, Bergfeld W. Diffuse hair loss: its triggers and management. Cleve Clin J Med. 2009 Jun;76(6):361-7. doi: 10.3949/ccjm.76a.08080. 
  8. Mason KA, Schoelwer MJ, Rogol AD. Androgens During Infancy, Childhood, and Adolescence: Physiology and Use in Clinical Practice. Endocr Rev. 2020 Jun 1;41(3):bnaa003. doi: 10.1210/endrev/bnaa003.
  9. Chaturvedi AP, Dehm SM. Androgen Receptor Dependence. Adv Exp Med Biol. 2019;1210:333-350. doi: 10.1007/978-3-030-32656-2_15. 
  10. Ceruti JM, Leirós GJ, Balañá ME. Androgens and androgen receptor action in skin and hair follicles. Mol Cell Endocrinol. 2018 Apr 15;465:122-133. doi: 10.1016/j.mce.2017.09.009.
  11. Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study. Am J Clin Dermatol. 2019 Feb;20(1):147-153. doi: 10.1007/s40257-018-0387-0. 
  12. Van Neste D, Fuh V, Sanchez-Pedreno P, Lopez-Bran E, Wolff H, Whiting D, Roberts J, Kopera D, Stene JJ, Calvieri S, Tosti A, Prens E, Guarrera M, Kanojia P, He W, Kaufman KD. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol. 2000 Oct;143(4):804-10. doi: 10.1046/j.1365-2133.2000.03780.x. 
  13. Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002 Jan-Feb;12(1):38-49. 
  14. Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014 Oct;52(10):842-9. doi: 10.5414/CP202119. 
  15. Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, Tamarit ML, Galván J, Tebbs V, Massana E; Topical Finasteride Study Group. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):286-294. doi: 10.1111/jdv.17738. Epub 2021 Oct 25. Erratum in: J Eur Acad Dermatol Venereol. 2023 Feb;37(2):452.
  16. Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016 Jan;54(1):19-27. doi: 10.5414/CP202467.
  17. Coskuner ER, Ozkan B, Culha MG. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors. Sex Med Rev. 2019 Apr;7(2):277-282. doi: 10.1016/j.sxmr.2018.07.003.
  18. Lee S, Lee YB, Choe SJ, Lee WS. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2019 Jan 1;99(1):12-17. doi: 10.2340/00015555-3035.
  19. Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. J Drugs Dermatol. 2018 Apr 1;17(4):457-463.
  20. Traish AM. The post-finasteride syndrome: clinical manifestation of drug-induced epigenetics due to endocrine disruption. Curr Sex Health Rep. 2018;10(3):88–103.
  21. Nguyen DD, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N, Trinh QD. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. JAMA Dermatol. 2021 Jan 1;157(1):35-42. doi: 10.1001/jamadermatol.2020.3385.
  22. Ahmed TA, El-Say KM. Transdermal film-loaded finasteride microplates to enhance drug skin permeation: Two-step optimization study. Eur J Pharm Sci. 2016 Jun 10;88:246-56. doi: 10.1016/j.ejps.2016.03.015.
  23. Escamilla-Cruz M, Magaña M, Escandón-Perez S, Bello-Chavolla OY. Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review. Dermatol Ther (Heidelb). 2023 Aug;13(8):1721-1731. doi: 10.1007/s13555-023-00974-4. 
  24. Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, Tamarit ML, Galván J, Tebbs V, Massana E; Topical Finasteride Study Group. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):286-294. doi: 10.1111/jdv.17738. 

Download Article
Received August 28, 2023.
Accepted October 12, 2023.
©2023 International Medical Research and Development Corporation.